Limits...
Oral Bromelain Attenuates Inflammation in an Ovalbumin-induced Murine Model of Asthma.

Secor ER, Carson WF, Singh A, Pensa M, Guernsey LA, Schramm CM, Thrall RS - Evid Based Complement Alternat Med (2008)

Bottom Line: Bromelain, a widely used pineapple extract with cysteine protease activity, has been shown to have immunomodulatory effects in a variety of immune system models.Oral bromelain-treatment of AAD mice demonstrated therapeutic efficacy as evidenced by decreased methacholine sensitivity (P </= 0.01), reduction in BAL eosinophils (P </= 0.02) and IL-13 concentrations (P </= 0.04) as compared with PBS controls.These results suggest that oral treatment with bromelain had a beneficial therapeutic effect in this murine model of asthma and bromelain may also be effective in human conditions.

View Article: PubMed Central - PubMed

Affiliation: Department of Immunology and Department of Pediatrics, University of Connecticut School of Medicine, Farmington, CT, USA.

ABSTRACT
Bromelain, a widely used pineapple extract with cysteine protease activity, has been shown to have immunomodulatory effects in a variety of immune system models. The purpose of the present study was to determine the effects of orally administered bromelain in an ovalbumin (OVA)-induced murine model of acute allergic airway disease (AAD). To establish AAD, female C57BL/6J mice were sensitized with intraperitoneal (i.p.) OVA/alum and then challenged with OVA aerosols for 3 days. Mice were gavaged with either (phosphate buffered saline)PBS or 200 mg/kg bromelain in PBS, twice daily for four consecutive days, beginning 1 day prior to OVA aerosol challenge. Airway reactivity and methacholine sensitivity, bronchoalveolar lavage (BAL) cellular differential, Th2 cytokines IL-5 and IL-13, and lung histology were compared between treatment groups. Oral bromelain-treatment of AAD mice demonstrated therapeutic efficacy as evidenced by decreased methacholine sensitivity (P

No MeSH data available.


Related in: MedlinePlus

Bromelain treatment protocol. Each animal was sensitized with 3 OVA-Alum i.p. injections 1 week apart (−21 days, −14 days, −7 days). Six days after the third injection (−1 day) each animal received either Bromelain (200 mg/kg) in 0.5 ml of phosphate buffered saline (PBS) or 0.5 ml PBS alone via gavage (orally). Treatment was administred twice daily (6–8 h apart) for 4 consecutive days. Animals were challenged with 1% OVA in saline for 1 h per day (0–3). All animals were sacrificed 12 h after the last treatment (day 3) and the primary AAD outcomes assessed.
© Copyright Policy - creative-commons
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC2249734&req=5

Figure 1: Bromelain treatment protocol. Each animal was sensitized with 3 OVA-Alum i.p. injections 1 week apart (−21 days, −14 days, −7 days). Six days after the third injection (−1 day) each animal received either Bromelain (200 mg/kg) in 0.5 ml of phosphate buffered saline (PBS) or 0.5 ml PBS alone via gavage (orally). Treatment was administred twice daily (6–8 h apart) for 4 consecutive days. Animals were challenged with 1% OVA in saline for 1 h per day (0–3). All animals were sacrificed 12 h after the last treatment (day 3) and the primary AAD outcomes assessed.

Mentions: Each animal received either bromelain (200 mg kg−1) in 0.5 ml of PBS or 0.5 ml PBS alone via gavage (orally) twice daily beginning 6 days after the third OVA–Alum sensitization injection (Fig. 1). The treatments were administered 6–8 h apart, and all animals were sacrificed ∼12 h after the last treatment and the primary AAD outcomes collected and assessed.Figure 1.


Oral Bromelain Attenuates Inflammation in an Ovalbumin-induced Murine Model of Asthma.

Secor ER, Carson WF, Singh A, Pensa M, Guernsey LA, Schramm CM, Thrall RS - Evid Based Complement Alternat Med (2008)

Bromelain treatment protocol. Each animal was sensitized with 3 OVA-Alum i.p. injections 1 week apart (−21 days, −14 days, −7 days). Six days after the third injection (−1 day) each animal received either Bromelain (200 mg/kg) in 0.5 ml of phosphate buffered saline (PBS) or 0.5 ml PBS alone via gavage (orally). Treatment was administred twice daily (6–8 h apart) for 4 consecutive days. Animals were challenged with 1% OVA in saline for 1 h per day (0–3). All animals were sacrificed 12 h after the last treatment (day 3) and the primary AAD outcomes assessed.
© Copyright Policy - creative-commons
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC2249734&req=5

Figure 1: Bromelain treatment protocol. Each animal was sensitized with 3 OVA-Alum i.p. injections 1 week apart (−21 days, −14 days, −7 days). Six days after the third injection (−1 day) each animal received either Bromelain (200 mg/kg) in 0.5 ml of phosphate buffered saline (PBS) or 0.5 ml PBS alone via gavage (orally). Treatment was administred twice daily (6–8 h apart) for 4 consecutive days. Animals were challenged with 1% OVA in saline for 1 h per day (0–3). All animals were sacrificed 12 h after the last treatment (day 3) and the primary AAD outcomes assessed.
Mentions: Each animal received either bromelain (200 mg kg−1) in 0.5 ml of PBS or 0.5 ml PBS alone via gavage (orally) twice daily beginning 6 days after the third OVA–Alum sensitization injection (Fig. 1). The treatments were administered 6–8 h apart, and all animals were sacrificed ∼12 h after the last treatment and the primary AAD outcomes collected and assessed.Figure 1.

Bottom Line: Bromelain, a widely used pineapple extract with cysteine protease activity, has been shown to have immunomodulatory effects in a variety of immune system models.Oral bromelain-treatment of AAD mice demonstrated therapeutic efficacy as evidenced by decreased methacholine sensitivity (P </= 0.01), reduction in BAL eosinophils (P </= 0.02) and IL-13 concentrations (P </= 0.04) as compared with PBS controls.These results suggest that oral treatment with bromelain had a beneficial therapeutic effect in this murine model of asthma and bromelain may also be effective in human conditions.

View Article: PubMed Central - PubMed

Affiliation: Department of Immunology and Department of Pediatrics, University of Connecticut School of Medicine, Farmington, CT, USA.

ABSTRACT
Bromelain, a widely used pineapple extract with cysteine protease activity, has been shown to have immunomodulatory effects in a variety of immune system models. The purpose of the present study was to determine the effects of orally administered bromelain in an ovalbumin (OVA)-induced murine model of acute allergic airway disease (AAD). To establish AAD, female C57BL/6J mice were sensitized with intraperitoneal (i.p.) OVA/alum and then challenged with OVA aerosols for 3 days. Mice were gavaged with either (phosphate buffered saline)PBS or 200 mg/kg bromelain in PBS, twice daily for four consecutive days, beginning 1 day prior to OVA aerosol challenge. Airway reactivity and methacholine sensitivity, bronchoalveolar lavage (BAL) cellular differential, Th2 cytokines IL-5 and IL-13, and lung histology were compared between treatment groups. Oral bromelain-treatment of AAD mice demonstrated therapeutic efficacy as evidenced by decreased methacholine sensitivity (P

No MeSH data available.


Related in: MedlinePlus